NCT04360655

Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC

A Randomized, Prospective Study of the Efficacy and Safety of the 1st Treatment in Advanced Central NSCLC by PD-1/PD-L1 Inhibitor and Chemotherapy With/Without Bronchoscopic Microwave Intervention

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A randomized, prospective study of the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention

Detailed description

This study is a randomized, prospective study, which will analyze the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention. The efficacy will include objective response rate, disease control rate, progression-free survival, and overall survival. The safety will include adverse events and quality of life.

Conditions

• Effect Increased
• Safety Issues

Interventions

Type	Name	Description
PROCEDURE	bronchoscopic microwave intervention	bronchoscopic microwave intervention
DRUG	anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy	anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy

Timeline

• Start date: 2020-05-01
• Primary completion: 2022-04-30
• Completion: 2023-05-01
• First posted: 2020-04-24
• Last updated: 2020-04-24